Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting·     New long-term data presented at AES 2025 ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Initial safety results for the full cohort of 19 indicated that the treatment was well tolerated. The only notable adverse ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

Xenon Pharmaceuticals (XENE) announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE ...

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...

The MarketWatch News Department was not involved in the creation of this content.-- Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including ...

Medical cannabis lacks adequate scientific backing for most of the conditions it is commonly used to treat, including chronic ...